SyStemix Inc. (NASDAQ-NMS:STMX) and Sandoz Pharma Ltd., aunit of Sandoz Ltd. (ADR:SDOZY), will end their collaboration todiscover human stem cell growth factor (SCGF) on June 30. Thecontract, entered into in June 1992, had a clause allowing thecollaboration to be terminated after 18 months.The arrangement earned SyStemix a total of $10.63 million inpayments from Sandoz in 1992 and 1993, Jessica Benjoya, a companyspokeswoman, said.Palo Alto, Calif.-based SyStemix will continue the search for thegrowth factor alone. However, it may team up again with Sandoz,which owns 60 percent of SyStemix's equity, on a different SCGFproject under a different contractual arrangement, Benjoya said.SyStemix and Sandoz, which is based in Basel, Switzerland, also havecollaborations in two other projects. One seeks to identify therapeuticantiviral agents for HIV infection. The other, a joint venture calledProgenysis, is working to develop hematopoietic cell-based genetherapies against HIV infection. These collaborations will continueunchanged. _ Philippa Maister
(c) 1997 American Health Consultants. All rights reserved.